We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Neoleukin Therapeutics Inc
9 own
15 watching
Current Price
$4.07
$0.05
(1.24%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
0
52-Week High
4.10000
52-Week Low
0.37500
Average Volume
0.04M
Dividend Yield
--
P/E Ratio
--
Market Capitalization052-Week High4.1000052-Week Low0.37500Average Volume0.04MDividend Yield--P/E Ratio--What does the Neoleukin Therapeutics Inc do?
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Read More
How much money does Neoleukin Therapeutics Inc make?
News & Events about Neoleukin Therapeutics Inc.
Globe Newswire
9 months ago
Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cellsSEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics...
Ticker Report
10 months ago
HC Wainwright cut shares of Neoleukin Therapeutics (NASDAQ:NLTX Get Rating) from a buy rating to a neutral rating in a research report report published on Wednesday morning, The Fly reports. HC Wainwright also issued estimates for Neoleukin Therapeutics Q2 2023 earnings at ($0.17) EPS...
Globe Newswire
11 months ago
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH...
Zolmax
1 year ago
Zacks Investment Research cut shares of Neoleukin Therapeutics (NASDAQ:NLTX Get Rating) from a buy rating to a hold rating in a research report report published on Friday morning, Zacks.com reports. According to Zacks, Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in ...
Globe Newswire
1 year ago
- NL-201 demonstrates antitumor activity in preclinical B-cell lymphoma models - - NL-201 synergizes with radiation therapy to generate potent, antitumor immunity - SEATTLE, April 13, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company ...
Frequently Asked Questions
Frequently Asked Questions
What is Neoleukin Therapeutics Inc share price today?
Can Indians buy Neoleukin Therapeutics Inc shares?
How can I buy Neoleukin Therapeutics Inc shares from India?
Can Fractional shares of Neoleukin Therapeutics Inc be purchased?
What are the documents required to start investing in Neoleukin Therapeutics Inc stocks?
What is today’s traded volume of Neoleukin Therapeutics Inc?
What is today’s market capitalisation of Neoleukin Therapeutics Inc?
What is the 52-Week High and Low Range of Neoleukin Therapeutics Inc?
What percentage is Neoleukin Therapeutics Inc down from its 52-Week High?
What percentage is Neoleukin Therapeutics Inc up from its 52-Week Low?
Current Price
$4.07
$0.05
(1.24%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.